Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health‐Related Quality of Life

医学 贝里穆马布 安慰剂 内科学 优势比 系统性红斑狼疮 红斑狼疮 生活质量(医疗保健) 临床试验 子群分析 析因分析 物理疗法 置信区间 疾病 免疫学 病理 替代医学 B细胞激活因子 抗体 B细胞 护理部
作者
Diogo Jesús,Carla Henriques,Ana Cristina Matos,Andrea. Schwartz Doria,Luís Inês
出处
期刊:Arthritis Care and Research [Wiley]
卷期号:76 (6): 788-795 被引量:5
标识
DOI:10.1002/acr.25305
摘要

OBJECTIVE: Our objective was to evaluate the ability of Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) remission and low disease activity (LDA) to discriminate active drug from placebo and to discriminate outcomes in the patients' perspective (health-related quality of life [HR-QoL]) in SLE trials. METHODS: This was a post hoc analysis of the pooled Belimumab in Subjects With SLE (BLISS)-52 (NCT00424476) and BLISS-76 (NCT00410384) trials data. SLE-DAS remission and LDA attainment and discrimination between belimumab and placebo at 52 weeks were compared using chi-square tests. At week 52, 36-item Short Form Health Survey (SF-36) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scores were compared between patients attaining SLE-DAS remission versus nonremission and SLE-DAS LDA versus non-LDA using the t-test and Mann-Whitney test. Mean changes from week 0 to 52 in SF-36 and FACIT-F scores were compared between groups using multivariate regression analysis adjusted for baseline scores. RESULTS: At week 52, significantly more patients attained SLE-DAS LDA taking belimumab 1 mg/kg (17.9% vs 13.0%; P = 0.023; odds ratio [OR] 1.459; relative risk [RR] 1.377; number needed to treat [NNT] 20.4) and 10 mg/kg (21.7% vs 13.0%; P < 0.001; OR 1.853; RR 1.668; NNT 11.5) compared with placebo. Likewise, more patients attained SLE-DAS remission taking belimumab 10 mg/kg compared to placebo (14.7% vs 10.1%; P = 0.019; OR 1.532; RR 1.454; NNT 21.7). At week 52, patients attaining SLE-DAS remission and LDA presented higher SF-36 domain and summary scores (all P < 0.001) and FACIT-F scores (both P < 0.001). Mean improvements from baseline in SF-36 and FACIT-F scores were significantly higher in patients achieving SLE-DAS remission and LDA. CONCLUSION: SLE-DAS remission and LDA showed discriminant ability for identifying patients receiving active drug in SLE clinical trials. Attainment of these SLE-DAS targets are associated with better HR-QoL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
廾匸完成签到,获得积分10
刚刚
lin发布了新的文献求助10
1秒前
wujun完成签到,获得积分10
3秒前
5秒前
6秒前
秃然完成签到,获得积分10
6秒前
wjw完成签到,获得积分10
7秒前
7秒前
CipherSage的应助被哇芽采纳,获得10
7秒前
崔正成完成签到,获得积分10
7秒前
在水一方的应助被坚强孤容采纳,获得10
8秒前
8秒前
bobopoi完成签到,获得积分10
8秒前
pear完成签到,获得积分10
8秒前
9秒前
凡凡完成签到,获得积分10
10秒前
Julian的应助被zzZZZ采纳,获得30
10秒前
一休完成签到 ,获得积分10
10秒前
mooncake187发布了新的文献求助10
11秒前
查找关注了科研通微信公众号
11秒前
李楠楠发布了新的文献求助10
11秒前
飘逸的又夏完成签到 ,获得积分10
12秒前
这就是你的回答吗完成签到 ,获得积分10
12秒前
12秒前
12秒前
13秒前
圥忈完成签到,获得积分10
13秒前
霡霂发布了新的文献求助10
13秒前
bobopoi发布了新的文献求助10
15秒前
胡图图发布了新的文献求助10
16秒前
小情绪发布了新的文献求助10
17秒前
西瓜翠衣完成签到,获得积分10
17秒前
17秒前
xing_xing的应助被一一采纳,获得20
18秒前
18秒前
fff发布了新的文献求助10
18秒前
19秒前
杨承武发布了新的文献求助10
19秒前
宇智波小小怪完成签到,获得积分10
19秒前
李楠楠完成签到,获得积分20
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186750
求助须知:如何正确求助?哪些是违规求助? 9575027
关于积分的说明 21839240
捐赠科研通 7784331
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611